SynthesisThe Cochrane database of systematic reviews2013
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism.
Synthesis in The Cochrane database of systematic reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.Blood advances · 2018Guideline
- Warfarin initiation nomograms for venous thromboembolism.The Cochrane database of systematic reviews · 2016Pooled it
- Anticoagulation strategies in patients with coexisting traumatic intracranial hematomas and cerebral venous sinus thrombosis: an observational cohort study.Acta neurochirurgica · 2024Observational
- New recommendations on cerebral venous and dural sinus thrombosis from the German consensus-based (S2k) guideline.Neurological research and practice · 2024Article
- Evaluation of the Safety and Efficacy of Enoxaparin Once-Daily Versus Twice-Daily Dosing for Prophylaxis in Pediatric Patients.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2024Article
- Management of thromboembolic disorders during pregnancy in resource-constrained settings: An Indian perspective.The Indian journal of medical research · 2023Review
- Prevalence of perioperative asymptomatic venous thromboses of the lower extremity in 30 consecutive patients undergoing transsphenoidal surgery for Cushing's disease.Scientific reports · 2023Article
- Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.European journal of clinical pharmacology · 2022Review
- Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation.Hematology. American Society of Hematology. Education Program · 2021Article
- What Do We Know about Thromboprophylaxis and Its Monitoring in Critically Ill Patients?Biomedicines · 2021Review
- Once-daily vs. twice-daily dosing of enoxaparin for the management of venous thromboembolism: A systematic review and meta-analysis.Experimental and therapeutic medicine · 2020Article
- Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?British journal of clinical pharmacology · 2017Review
- Guidance for the treatment and prevention of obstetric-associated venous thromboembolism.Journal of thrombosis and thrombolysis · 2016Article
Corrections and comments
- Update of
Authors and funding
2 authors.
Funding
Abstract
backgroundIn the initial treatment of venous thromboembolism (VTE) low molecular weight heparin (LMWH) is administered once or twice daily. A once daily treatment regimen is more convenient for the patient and may optimise home treatment. However, it is not clear whether a once daily treatment regimen is as safe and effective as a twice daily treatment regimen. This is the second update of a review first published in 2003.
objectivesTo compare the efficacy and safety of once daily versus twice daily administration of LMWH. SEARCH
methodsFor this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched May 2013) and CENTRAL (2013, Issue 4). SELECTION CRITERIA: Randomised clinical trials in which LMWH given once daily is compared with LMWH given twice daily for the initial treatment of VTE. DATA COLLECTION AND ANALYSIS: Two review authors assessed trials for inclusion and extracted data independently. MAIN
resultsFive studies were included with a total of 1508 participants. The pooled data showed no statistically significant difference in recurrent VTE between the two treatment regimens (OR 0.82, 0.49 to 1.39; P = 0.47). A comparison of major haemorrhagic events (OR 0.77, 0.40 to 1.45; P = 0.41), improvement of thrombus size (OR 1.41, 0.66 to 3.01; P = 0.38) and mortality (OR 1.14, 0.62 to 2.08; P = 0.68) also showed no statistically significant differences between the two treatment regimens. None of the five included studies reported data on post-thrombotic syndrome. AUTHORS'
conclusionsOnce daily treatment with LMWH is as effective and safe as twice daily treatment with LMWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.